FUJIFILM Biotechnologies expanded manufacturing and process development presence in the North East of England to support vital biomanufacturing innovativ...
BioArctic AB's (publ) (NASDAQ: BIOA B (Stockholm: BIOA B) partner Eisai announced that the Biologics License Application (BLA) for the treatme...
Life sciences innovator and leader in precision-engineered synthetic cell mimic technology expands its UK/EU operations to accelerate cell and gene thera...
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), announced a collaboration with the Stanford Center for Definitive and C...
Agreement includes eight programmes, including a clinical-ready asset, plus access to advanced AI-driven peptide drug discovery platform and innovati...
Leading GMP cell therapy CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that it ha...
Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating tre...
Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, announced that the U.S. Food and Drug ...
Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, to...
Charles River Laboratories International, Inc. (NYSE: CRL) and Gazi University Faculty of Medicine, announced a gene therapy contract developme...
The phase 3 trial DELTA CARE 1 will recruit up to 652 adult patients with lichen sclerosus (LS) to investigate the efficacy and safety of delgocitini...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, announced updated efficacy and safety results from the ongoing QUILT-106 clin...
This further establishes the global leadership of AGC Biologics' Milan Cell and Gene Center of Excellence in number of commercial products approved ...
Ouroboros Family Founders Fund I, LP announced this week it will lead a $60 million Series A financing in Cytotheryx, Inc., a preclinical cell therapy comp...
© 2026 Biopharma Boardroom. All Rights Reserved.
